雌激素受体向剂在乳腺癌中的进展和挑战
Jie Hu1, Songyang Zhong1, Huayu Sun1
1Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, 324000, China.
Archives of pharmacal research
|November 16, 2025
概括
针对雌激素受体 (ERs) 的新疗法对乳腺癌有希望,但耐药性和副作用等挑战仍然存在. 在ER降解方面的创新为改善治疗效率和克服局限性提供了新的策略.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 雌激素受体 (ERs) 是 ~ 70% 的乳腺癌的关键点.
- 目前针对ER的药物 (SERM,SERD) 有局限性,包括副作用,耐药性和不良的药理动力学.
研究的目的:
- 审查针对乳腺癌的ER向药物开发的最新进展.
- 讨论新型药物和降解策略,以克服当前的治疗挑战.
主要方法:
- 关于ER向治疗的最新进展的文献综述.
- 对新型ER向剂和创新的降解技术的分析.
主要成果:
- 开发第三代SERM,口服SERD和其他新型药物.
- 为ER降解而出现的向蛋白质溶解的嵌合体,分子,以及向 lysosome 的嵌合体.
- 尽管取得了进展,但只批准了两种针对ER的药物,突出显示了临床翻译障碍.
结论:
- 在开发新型ER向药物和降解策略方面取得了重大进展.
- 临床转化仍然存在挑战,需要进一步的研究.
- 未来的抗ER疗法有可能改善乳腺癌的治疗.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle
7.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
414
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
414
Transducer Mechanism: Nuclear Receptors
2.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
2.3K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K


